Jan 15, 2020   SOURCE: PR NewsWire

Inhalable Drugs Market Size to Hit US$ 41.5 Billion by 2026

LOS ANGELES, Jan. 15, 2020 /PRNewswire/ -- The global inhalable drugs market is expected to grow at a CAGR of around 6.4% from 2019 to 2026 and reach the market value of over US$ 41.5 Bn by 2026.

Free Download Sample Report Pages for Better Understanding@ https://www.acumenresearchandconsulting.com/request-sample/1663

In 2018, North America held the large number of market share for inhalable drugs market and the region is projected to maintain its dominance over the forecast period. The region is primarily gaining growth owing to the easy availability of advanced products. According to the Centers for Disease Control and Prevention (CDC), more than 25 million Americans have asthma, which includes 7.7 percent adult and 8.4 percent children. The asthma disease is increasing, since the 1980's in all sex and age. In addition, in 2017, an average of 10 Americans have died from asthma which is approximately 3,564 people.

Furthermore, Asia Pacific is expected to be the fastest-growing market over the forecast period. The increasing disposable income along with the rising awareness among individuals about the advance technologies for the treatment of diseases is supporting the regional market growth. In addition, the increasing governmental support for the development of healthcare infrastructure in the region is further propelling the market value.

View Detail Information with Complete TOC@ https://www.acumenresearchandconsulting.com/inhalable-drugs-market

Based on type, the dry powder formulation segment held the major share in the global inhalable drugs market in 2018. The emerging expertise in dry powder formulation of potent drugs is enabling cheap and simple development which is favoring the market growth. For instance, Glenmark Pharmaceuticals signed an agreement in 2018 to commercialize Tiotropium Bromide dry powder inhaler in the Europe region to treat patients with chronic obstructive pulmonary disease (COPD).

Respiratory diseases accounted for the major share in the inhalable drugs market in the year 2018. The segment is primarily gaining growth owing to the rising prevalence of respiratory diseases. According to the WHO, the top 10 causes of death across the globe include lung cancer, COPD, tuberculosis, and lower respiratory infections. The favorable government initiatives, good reimbursement policies, and the increasing cases of tobacco smoking are favoring the segment growth. The increasing awareness program is further supporting the segment growth. For instance, In 2016, Mylan N.V. has organized chronic obstructive pulmonary disease (COPD) Awareness Month to spread awareness about various treatments including inhaled and other bronchodilators along with their different dosage forms.

Related Reports

    --  Ophthalmic Drugs Market - The global market value is expected to reach
        around US$ 40 billion by 2026 growing at noteworthy CAGR of 4.2 %
        throughout the forecast period 2019 to 2026.
    --  Over-the-Counter (OTC) Drugs Market - The global market was valued over
        US$ 120 Bn in the year 2018. The market is expected to witness
        significant growth rate of 5.8% over forecast period.
    --  Probiotics Market - Global market value is expected to reach around US$
        78 billion by 2026 growing at noteworthy CAGR around 6.6 % over the
        forecast period 2019 to 2026.

Some of the leading competitors are AstraZeneca, Sanofi, Vectura, Mylan, GlaxoSmithKline, Mundipharma, Boehringer Ingelheim International GmbH, Cipla Inc. and Others. Inhalable drug companies have announced mergers and acquisitions to expand their position in the inhalable drug industry. Major players are also moving into new regions or advanced technologies. For instance, MannKind Corporation developed and commercialized FDA approved Afrezza, an inhalation powder for diabetes patients in 2019.

Some of the key observations regarding inhalable drugs industry include:

    --  GlaxoSmithKline Plc or gsk, a British drugmaker has announced that its
        three in one drug named Trelegy has met the main goal of asthma, which
        is expected to boost the lung medicines division of the company that was
        prior hit by the generic competition.
    --  In 2019, Breath Therapeutics a private company has announced the
        initiation of global Phase 3 trials for the treatment of Bronchiolitis
        Obliterans Syndrome (BOS).
    --  In 2019, Cipla Limited has launched first extra-fine particle inhaler
        developed in India named Niveoli. It is India's first extrafine ICS-LABA
        combination hydrofluoroalkane inhaler.
    --  In 2019, The European Medicines Agency (EMA) Committee for Medicinal
        Products for Human Use (CHMP) has approved the inhaled form of levodopa
        for the intermittent treatment of episodic motor fluctuations in
        Parkinson's disease (PD).
    --  EffRx Pharmaceuticals and Pharmaxis have signed an agreement in 2019 to
        commercialize Bronchitol (mannitol) in Switzerland for the treatment of
        cystic fibrosis (CF). In addition, according to the Swiss Society for
        Cystic Fibrosis (CFCH), around 1,000 people were affected by CF in
        Switzerland.
    --  TFF Pharmaceuticals Inc. has announced the initiation of Phase 1
        Clinical Trial of inhaled Voriconazole in the year 2019 for the
        treatment of Invasive Pulmonary Aspergillosis.
    --  Alaxia joined iABC, a European consortium in 2019 to speed up the
        development of ALX-009. ALX-009 is an investigational inhaled antibiotic
        for multi-drug resistant lung infections in cystic fibrosis patients.

Request for Customization@ https://www.acumenresearchandconsulting.com/request-customization/1663

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this premium research report@ https://www.acumenresearchandconsulting.com/buy-now/0/1663

If you would like to place an order or have any questions, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157 OR +1 408 900 9135

About Us

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. Among the industries served include aerospace and defense, information and communication technology (ICT), semiconductor and electronics, healthcare and pharmaceuticals, chemicals, advanced materials, banking, finance services and insurance (BFSI), and others.

Our collective industry experience of over 100 years has helped us to offer appropriate market information and our global reach and regional connects ensures appropriate insights into regional markets to guarantee apt delivery of information.

Our regional market intelligence helps our clients to identify potential opportunities and develop growth strategies across regions and countries. Our services are geared towards offering best market research to our clients.

Contact Us:
Mr. Frank Wilson
Acumen Research and Consulting
17890, Castleton St #218, Rowland Heights, CA 91748 United States
Tel: USA: +1 407 915 4157 OR +1 408 900 9135
Asia : +91-898-322-5533
Email: sales@acumenresearchandconsulting.com
Website: https://www.acumenresearchandconsulting.com

View original content:http://www.prnewswire.com/news-releases/inhalable-drugs-market-size-to-hit-us-41-5-billion-by-2026--300987737.html

SOURCE Acumen Research and Consulting